US 2003/0170838 A1Published application

Novel polynucleotides and polypeptides encoded thereby

OwnerVishnu S. Mishra, Kimberly Ann Spytek +19inventors

InventorsVishnu S. Mishra, Kimberly Ann Spytek, Raymond J. Taupier JR., Corine A. Vernet, Steven D. Colman, Linda Gorman, Velizar T. Tchernev, Uriel M. Malyankar, Suresh Shenoy, Muralidhara Padigaru, Valerie L. Gerlach, John R. MacDougall, Glennda Smithson, Isabelle Millet, John Peyman, David Stone, Erik Gunther, Karen Ellerman, Li Li, Luca Rastelli, Bryan Zerhusen

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

Disclosed herein are nucleic acid sequences that encode Wnt, zinc transporter, mitsugumin29, slit-3, LRR/GPCR, major histocompatability complex enhancer protein MAD3, interleukin 9, 5-hydroxytryptamine receptor, and thioredoxin related polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

Claims43

Dependent claims

An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, and 32;
(b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, and 32, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;
(c) an amino acid sequence selected from the group consisting SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, and 32;
and
(d) a variant of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, and 32;
wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence.

3 more elements

An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:

(a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, and 32;
(b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, and 32, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;
(c) an amino acid sequence selected from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, and 32;
(d) a variant of an amino acid sequence selected from the group consisting SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, and 32, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence;
(e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising an amino acid sequence chosen from the group consisting of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, and 32, or a variant of said polypeptide, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence;
and
(f) a nucleic acid molecule comprising the complement of (a), (b), (c), (d) or (e).

4 more elements

Dependencies are inferred from the claim text.

Facts

Application: 09/954,342Filed 17 Sep 2001
Priority: 15 Sep 2000
Published: 11 Sep 2003
Term ends: Not estimatedThe source records don’t support an estimate.

Classification11 codes

A61B 10/0275
Means for severing sample: with sample notch, e.g. on the side of inner stylet
A61P 35/00
Antineoplastic agents
C07K 14/475
From animals; from humans: growth factors; Growth regulators
C07K 14/5425
Interleukins [IL]: il-9

Family

Application60/232,675Us provisional application · filed 15 Sep 2000
Application60/232,676Us provisional application · filed 15 Sep 2000
Application60/232,679Us provisional application · filed 15 Sep 2000
Application60/233,382Us provisional application · filed 18 Sep 2000
Application60/233,402Us provisional application · filed 18 Sep 2000
Application60/233,801Us provisional application · filed 19 Sep 2000
Application60/233,521Us provisional application · filed 19 Sep 2000
Application60/233,522Us provisional application · filed 19 Sep 2000
Application60/233,960Us provisional application · filed 20 Sep 2000
Application60/238,398Us provisional application · filed 6 Oct 2000
Application60/240,498Us provisional application · filed 13 Oct 2000
Application60/260,284Us provisional application · filed 8 Jan 2001
Application60/260,973Us provisional application · filed 11 Jan 2001
Application60/264,794Us provisional application · filed 29 Jan 2001
Application60/274,862Us provisional application · filed 9 Mar 2001
US 2003/0170838 A1This patent

From the US filing history. Foreign family members aren’t listed.